HIV is a big business for BIG PHARMA. They like to take their time, because it may hurt their sales in the short term. They are always wanting long term customers, so, rarely do they work on providing cures.
That is a great question! I unfortunately do not think anyone has a definitive answer for this yet. This would likely take a while for everyone to have access to it because it needs to be approved for human use which requires rigorous testing
@@trader2.094 There are multiple factors to this, one of the major ones is that covid affects all populations across the world, not just a subset. Covid is also a very transmissible disease that was having a higher mortality rate than other easily transmissible diseases like the flu, so there was a greater imperative to develop something quickly.
@@InvestigateExploreDiscover Yes true, you dont get hiv only being near someone together. Plus the vaccine train your immune system but what about a virus who hit directly your immune system? So it's not so easy to devolop a vaccine for hiv and I was surprised they could devolp one more than a cure. Moreover we are able not to eradicate the hiv virus from your body but we are able to stop it even if you have to get your medicine for all your life. Let's say they are a total different viruses with different consequences
Do we know something about the safety of this drug?. Looks promising but i guess we still don't have data on its safety or its pharmacokinetic properties in humans.
This information is available to the public. This info in particular is available at www.ncbi.nlm.nih.gov/pmc/articles/PMC7396128/. Pubmed is also a great source for looking up newly published scientific literature
But going in every month is not so great, getting an appointment too etc. I get tired of taking hiv meds every day. I also get stomach issues from it too, I sometimes forget or don’t feel like taking it.
I wish that I could give you an answer, I really don't know. This paper just highlights there initial use in cell culture and in humanized mouse models. My best guess is that it would take a while to be approved for human use because of all of the rigorous testing required
Bictegravir/Emtricitabine/Tenofovir Alafenamide is another drug being investigated for treating HIV which has phase 3 clinical trials slated to be completed in July 2022, which has a different mechanism of action from GS-CA1. So far there has been no wide-spread cure for HIV, only iways to be able to manage viral load throughout the patients lifetime.
Can I ask Dr...what does it means...when you take paralle tests..one gives positive results.then the other gives negative results..and have done this repeteadly..bt still it gives the same results
Can you please describe this issue some more? I am not entirely sure what you mean. If you have samples that are meant to be positive and negative, and they consistently give you those results, they sound like your positive and negative controls
l love Dr Pius Ozigbe! My daughter and I loved watching him and his sister in operation Ouch and his "Dr who gave up drugs" He seems like such a genuine, empathetic, no bullshit guy who genuinely cares and makes complex issues easy to understand for the lay person❤❤
GS-CA1 is not either of those drugs. It is similar to lenacapavir (GS-CA2), as they are both capsid inhibitors. Lenacapavir and cabenuva are also injectable HIV drugs that are undergoing clinical trials/ been approved in Canada
@@InvestigateExploreDiscover How long GS-CA1 will be efective in human body?, only 2 months?..Cabenuva has done this, except for 2 months therapy (still in clinical trial).
@@InvestigateExploreDiscover Btw, what is other benefits of this drugs than just long lasting injection only?, Could this drug inhibit latent reservoirs?.
@@antonanton1736 These are some good questions! I would like to know the answers to them as well. It remains unknown how long GS-CA1 will be effective in the human body for, as these studies have not been performed. There is also not enough information to determine whether GS-CA1 could inhibit latent reservoirs. It might be inferred that it acts in a similar fashion to lenapacavir, but more tests need to be done to determine these answers for certain.
@@InvestigateExploreDiscover Btw, I have found some interesting articles. It is peptide of F9170, and the exploration of this peptide is new (maybe 1 year ago). Could you please explore this peptide (F9170) on your next video. Link article: stm.sciencemag.org/content/12/546/eaaz2254/tab-figures-data
This guy first do not have any image presentation he need a hair cut, he does not have any credibility, how come you can stop it for one month and you can not do it forever, he is a clown
GS-CA1 (Lenacapavir Sodium, marketed by Gilead Sciences as Sunlenca) is not intended to be used as a single drug monotherapy regimen; it is intended to be used in addition to an Optimised Background Regimen. HIV is infamous for its ability to mutate quite quickly and quite often (particularly because of its lack of proofreading enzymes and single-strand RNA makeup). Therefore, no single antiretroviral drug or drug class should be used on its own when treating a patient with HIV. But it appears that Sunlenca/Lenacapavir/GS-CA1 has a very high barrier to resistance, and there is no evidence of cross-resistance to other classes of Antiretroviral drugs, although aquired resistance is possible if a fully supressive regimen is not constructed for a patient being treated with Sunlenca. However; a study has suggested that the efficacy and treatment responsiveness of Lenacapavir in suppressing HIV-2 infection is about 15-25% less potent. Clinical trials are being conducted with Merck's investigational drug Islatravir, a novel Nucleoside Reverse Transcriptase Translocation Inhibitor, as well another clinical trial with patients taking oral Lenacapavir combined with Gilead's own INSTI Bictegravir (the anchor drug in Biktarvy). The cost of Sunlenca (Lenacapavir/GS-CA1) is one of the most expensive on the market; with the lead-in dose costing $3432 for 4 tablets ($858 per tablet) and $39,000 for a year's worth of injections over 52 weeks ($9,750 per shot, $19,500 every 26 weeks).
HIV is a big business for BIG PHARMA. They like to take their time, because it may hurt their sales in the short term. They are always wanting long term customers, so, rarely do they work on providing cures.
Si de echo ya hay cura pero malditas farmacéuticos no quieren perder sus millones de dólares
When this treatment would be available in Sierra Leone and when it was discovered
When is it going to be available for everyone to access it.
That is a great question! I unfortunately do not think anyone has a definitive answer for this yet. This would likely take a while for everyone to have access to it because it needs to be approved for human use which requires rigorous testing
@@InvestigateExploreDiscover why was covid vaccine given to humans so fast?
@@trader2.094 There are multiple factors to this, one of the major ones is that covid affects all populations across the world, not just a subset. Covid is also a very transmissible disease that was having a higher mortality rate than other easily transmissible diseases like the flu, so there was a greater imperative to develop something quickly.
@@InvestigateExploreDiscover Yes true, you dont get hiv only being near someone together. Plus the vaccine train your immune system but what about a virus who hit directly your immune system? So it's not so easy to devolop a vaccine for hiv and I was surprised they could devolp one more than a cure. Moreover we are able not to eradicate the hiv virus from your body but we are able to stop it even if you have to get your medicine for all your life. Let's say they are a total different viruses with different consequences
Awesome now I can sell my house and buy one shot of my hiv therapy 🙂
Can you do a report on mr1 restricted t cell therapy and where it can be accessed via a trial or as a private patient? Thku
What if any side effects can one expect
Do we know something about the safety of this drug?. Looks promising but i guess we still don't have data on its safety or its pharmacokinetic properties in humans.
Instead of UA-cam this should be on international platforms.
Cure for same should also be released.
This information is available to the public. This info in particular is available at www.ncbi.nlm.nih.gov/pmc/articles/PMC7396128/. Pubmed is also a great source for looking up newly published scientific literature
La cura ya exacto
But going in every month is not so great, getting an appointment too etc. I get tired of taking hiv meds every day. I also get stomach issues from it too, I sometimes forget or don’t feel like taking it.
Animo amigo Mike solo falta poco para la cura ya estámos en el futuro
When will this be in india?
I wish that I could give you an answer, I really don't know. This paper just highlights there initial use in cell culture and in humanized mouse models. My best guess is that it would take a while to be approved for human use because of all of the rigorous testing required
This drug comes into effect as Sir
As I head, it’s September 2022. I heard that Canada and Europe has approved it. But is still quiet expensive
Drug , B/F/TAF: Curing Ratio?
Bictegravir/Emtricitabine/Tenofovir Alafenamide is another drug being investigated for treating HIV which has phase 3 clinical trials slated to be completed in July 2022, which has a different mechanism of action from GS-CA1. So far there has been no wide-spread cure for HIV, only iways to be able to manage viral load throughout the patients lifetime.
Excellent explanation. Clear and concise and makes it easy to understand. This guy should be who's sponsored rather than dumb-asses -Jess
Can you do a lecture on peptides for white blood cells?
how can someone get the gsca1 in Nigeria
Can I ask Dr...what does it means...when you take paralle tests..one gives positive results.then the other gives negative results..and have done this repeteadly..bt still it gives the same results
Can you please describe this issue some more? I am not entirely sure what you mean.
If you have samples that are meant to be positive and negative, and they consistently give you those results, they sound like your positive and negative controls
l love Dr Pius Ozigbe! My daughter and I loved watching him and his sister in operation Ouch and his "Dr who gave up drugs" He seems like such a genuine, empathetic, no bullshit guy who genuinely cares and makes complex issues easy to understand for the lay person❤❤
Lenacapavir or Cabenuva?...
GS-CA1 is not either of those drugs. It is similar to lenacapavir (GS-CA2), as they are both capsid inhibitors. Lenacapavir and cabenuva are also injectable HIV drugs that are undergoing clinical trials/ been approved in Canada
@@InvestigateExploreDiscover How long GS-CA1 will be efective in human body?, only 2 months?..Cabenuva has done this, except for 2 months therapy (still in clinical trial).
@@InvestigateExploreDiscover Btw, what is other benefits of this drugs than just long lasting injection only?, Could this drug inhibit latent reservoirs?.
@@antonanton1736 These are some good questions! I would like to know the answers to them as well.
It remains unknown how long GS-CA1 will be effective in the human body for, as these studies have not been performed. There is also not enough information to determine whether GS-CA1 could inhibit latent reservoirs. It might be inferred that it acts in a similar fashion to lenapacavir, but more tests need to be done to determine these answers for certain.
@@InvestigateExploreDiscover Btw, I have found some interesting articles. It is peptide of F9170, and the exploration of this peptide is new (maybe 1 year ago). Could you please explore this peptide (F9170) on your next video.
Link article: stm.sciencemag.org/content/12/546/eaaz2254/tab-figures-data
Roll it out now
God protect me please 🙏 this world
This guy first do not have any image presentation he need a hair cut, he does not have any credibility, how come you can stop it for one month and you can not do it forever, he is a clown
You are both nuts.
Elyuma heres genial exacto si hay cura este tipo no tiene idea de lo que abla
GS-CA1 (Lenacapavir Sodium, marketed by Gilead Sciences as Sunlenca) is not intended to be used as a single drug monotherapy regimen; it is intended to be used in addition to an Optimised Background Regimen. HIV is infamous for its ability to mutate quite quickly and quite often (particularly because of its lack of proofreading enzymes and single-strand RNA makeup). Therefore, no single antiretroviral drug or drug class should be used on its own when treating a patient with HIV. But it appears that Sunlenca/Lenacapavir/GS-CA1 has a very high barrier to resistance, and there is no evidence of cross-resistance to other classes of Antiretroviral drugs, although aquired resistance is possible if a fully supressive regimen is not constructed for a patient being treated with Sunlenca. However; a study has suggested that the efficacy and treatment responsiveness of Lenacapavir in suppressing HIV-2 infection is about 15-25% less potent. Clinical trials are being conducted with Merck's investigational drug Islatravir, a novel Nucleoside Reverse Transcriptase Translocation Inhibitor, as well another clinical trial with patients taking oral Lenacapavir combined with Gilead's own INSTI Bictegravir (the anchor drug in Biktarvy). The cost of Sunlenca (Lenacapavir/GS-CA1) is one of the most expensive on the market; with the lead-in dose costing $3432 for 4 tablets ($858 per tablet) and $39,000 for a year's worth of injections over 52 weeks ($9,750 per shot, $19,500 every 26 weeks).